La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alibaba Gr Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alibaba Gr Hldgs..

Alibaba Gr Hldgs (OTC:BABAF) Azioni, Catena delle Opzioni

Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.

Alibaba Group Holding Ltd. (BABA)

Equities

News

Markets

Tech

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

Il gigante cinese lancia un&#39;innovativa IA che legge le emozioni: una mossa audace per competere con i leader del settore.

Alibaba rivoluziona l&#39;IA: nuovo modello emozionale e gratuito sfida OpenAI

Mentre il colosso cinese cavalca l&#39;onda dell&#39;intelligenza artificiale, l&#39;impennata del valore azionario genera ottimismo.

Alibaba: il boom dell&#39;IA spinge il titolo al rialzo. Fuoco di paglia o rinascita?

Alibaba Group Holding Ltd

Barclays analyst Betty Jing maintains XPLR Infr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XIFR#NYSE">XIFR</a>) with a Underweight and lowers the price target from $7 to $6.

Price Target

Analyst Ratings

XIFR

Barclays Maintains Underweight on XPLR Infr, Lowers Price Target to $6

BMO Capital analyst Ketan Mamtora upgrades Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) from Market Perform to Outperform and maintains the price target from $72 to $72.

Upgrades

TREX

BMO Capital Upgrades Trex Co to Outperform, Maintains Price Target to $72

<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44300120/binance-ceo-richard-teng-hails-donald-trumps-bitcoin-reserve-xrp-ethereum-solana-digital-asset-stockpile">Crypto exchange Binance</a> is now actively assisting several countries in drafting crypto regulations and establishing national digital asset reserves, according to CEO Richard Teng.
What Happened: The move comes amid shifting global sentiment following the United States' more favorable stance on cryptocurrencies under President Donald Trump, the Financial Times <a href="https://www.ft.com/content/afd62059-9bb8-43b3-9395-65dd92a94d33">reported</a> on Thursday.
"Compared to many other jurisdictions, [the US] are way ahead on that front," Teng said in an interview, pointing to recent American plans to create a legal framework for digital assets and build a <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44816721/bitcoin-price-rips-through-86k-as-strategic-reserve-push-gains-global-traction">strategic reserve of Bitcoin</a>.
This policy shift has prompted other nations to seek guidance from Binance. 
Teng said the exchange has been "approached by quite a lot" of governments requesting help with their regulatory frameworks. 
While he declined to name specific countries, both Pakistan and Kyrgyzstan recently confirmed they are working with Binance founder Changpeng Zhao to shape local crypto policies.
The surge in demand for regulatory advice comes despite Binance's recent legal troubles. 
In 2023, the exchange pleaded guilty to charges related to money laundering and violating international sanctions, paying over $4.3 billion in penalties. 
Zhao stepped down as CEO and later served a four-month prison sentence. 
Under new leadership, Binance has implemented structural reforms, with nearly 25% of its 6,000-strong workforce now dedicated to compliance.
The United States has also placed Binance under a five-year compliance monitoring program led by the Financial Crimes Enforcement Network. 
Teng said the company's internal changes have made it "a form and shape that regulators appreciate much more compared to the past."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44843430/panama-city-council-now-accepts-bitcoin-ethereum-for-taxes-fines-fees">Panama City Council Now Accepts Bitcoin, Ethereum For Taxes, Fines, Fees</a>
Why It Matters: Binance's evolving regulatory role is complemented by its involvement in helping countries establish <a href="https://www.benzinga.com/news/25/04/44778849/peter-schiff-says-trumps-strategic-bitcoin-reserve-is-already-down-over-12-claims-if-wed-bought-gold-instead-wed-be-up-2-right-now">crypto reserves</a>.
Teng noted growing interest from sovereign wealth funds and national governments in building strategic holdings of digital assets.
"We have actually received quite a number of approaches," he said.
Trump's administration has contributed to this momentum. 
Last month, the U.S. announced the formation of a national Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reserve using assets seized by law enforcement, now totaling approximately $17.1 billion on Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), according to Arkham. 
However, the announcement disappointed some market participants who had anticipated large-scale government purchases to boost demand.
Although Bitcoin reached an all-time high of $108,000 after Trump's election win, the asset has since dropped over 15% amid concerns about his aggressive tariff policies. 
Still, proponents of a bitcoin reserve argue it can serve as a hedge against fiat currency debasement, positioning bitcoin as a modern-day "digital gold."
The return of Trump to the White House has also altered Binance's standing in the U.S. market. 
Teng confirmed that the SEC had paused its investigation into Binance and its U.S. affiliate, and that talks toward a potential resolution were underway.
Trump-affiliated entities are also deepening ties with Binance. 
<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44749223/trump-affiliated-world-liberty-financial-denies-8-million-ethereum-sell-off-loss">World Liberty Financial</a>, a crypto initiative associated with the Trump family, is planning to launch a stablecoin using Binance's blockchain infrastructure.
As Binance works to rebuild trust and credibility, Teng said the company is "working very hard" on choosing a location for a global headquarters, an unprecedented step for the exchange, which has historically avoided a formal base of operations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44839868/coinbase-warns-of-crypto-bear-market-but-says-a-recovery-in-2025-is-possible">Coinbase Warns Of Crypto Bear Market, But Says A Recovery In 2025 Is Possible</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

Binance Advising Nations On Strategic Bitcoin Reserves, Crypto Regulation: Report

Benchmark analyst Christopher Kuhn maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Buy and lowers the price target from $175 to $165.

JBHT

Benchmark Maintains Buy on JB Hunt Transport Servs, Lowers Price Target to $165

Susquehanna analyst Christopher Stathoulopoulos maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Positive and lowers the price target from $90 to $81.

Susquehanna Maintains Positive on United Airlines Holdings, Lowers Price Target to $81

Susquehanna analyst Mehdi Hosseini maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Positive and lowers the price target from $265 to $250.

Susquehanna Maintains Positive on Taiwan Semiconductor, Lowers Price Target to $250

Benchmark analyst Nathan Martin reiterates CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Buy and maintains $35 price target.

Reiteration

Benchmark Reiterates Buy on CSX, Maintains $35 Price Target

Susquehanna analyst Bascome Majors maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Neutral and lowers the price target from $165 to $140.

Susquehanna Maintains Neutral on JB Hunt Transport Servs, Lowers Price Target to $140

D. Boral Capital analyst Jason Kolbert maintains Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Buy and maintains $15 price target.

NNOX

D. Boral Capital Maintains Buy on Nano X Imaging, Maintains $15 Price Target

Susquehanna analyst Bascome Majors maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Positive and lowers the price target from $37 to $35.

Susquehanna Maintains Positive on CSX, Lowers Price Target to $35

Susquehanna analyst Mehdi Hosseini maintains ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) with a Positive and lowers the price target from $1100 to $965.

ASML

Susquehanna Maintains Positive on ASML Holding, Lowers Price Target to $965

What an eventful week in the markets. Bitcoin swung $10,000—trading from a weekly low of $74,000 and ending around $84,000 by Friday.
Over the past few weeks, the markets have experienced a strong risk-off narrative—but not just any kind. It's a U.S.-focused risk-off environment, where even safe-haven assets like U.S. Treasuries aren't seeing any love.
With typically safe-haven assets like U.S. Treasuries and the U.S. dollar not showing strength during times when they usually would, a narrative has emerged for Bitcoin to potentially step up to the plate.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
And with that, Bitcoin has definitely gotten a hit. I wouldn't call it a home run just yet, but its relative strength—holding above $80K during this period of geopolitical uncertainty, while stocks, bonds, and the U.S. dollar fall—should tell us something.
6-Month Historical Performance
If you had bought the S&amp;P 500 six months ago, prior to the U.S. election, you'd currently be down roughly 10% on your investment. Bitcoin, on the other hand, would have you up over 20%.
Once again, this highlights Bitcoin's relative strength compared to traditional markets, especially as uncertainty has played a major role.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="771" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073035/IMG_6982-1024x771.png" alt="" class="wp-image-874034" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073035/IMG_6982-1024x771.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073035/IMG_6982-300x226.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073035/IMG_6982-768x578.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073035/IMG_6982.png 1435w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Screenshot via Godel Terminal user Nick Thomas
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Daily Chart
As of writing this on Friday, there are still two trading days left before a new weekly candle forms in the crypto markets—so things could change. But for now, Bitcoin has made a strong move back inside the range after briefly trading below the key swing level.
With this in mind, we now have important key levels to monitor. If Bitcoin can reclaim these levels, we could start to see a significant shift in the market—potentially leading to a move back toward the all-time highs.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983-1024x538.png" alt="" class="wp-image-874033" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983-1536x807.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16073015/IMG_6983.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Screenshot via TradingView User NoticeTrades
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
If Bitcoin continues to trade higher heading into the weekend and next week, watching the $88K range will be crucial, as we've seen the market reject from that level twice now.
The next major level to break and reclaim is $92,000, which marks the low end of the previous consolidation.
In my view, if Bitcoin can strongly reclaim the $90,000s, we could see new all-time highs relatively quickly.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

Bitcoin Surges Past $82K Despite U.S. Risk-Off Mood — Is a Breakout Brewing?

Evercore ISI Group analyst David Motemaden maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Outperform and raises the price target from $288 to $296.

Evercore ISI Group Maintains Outperform on Travelers Companies, Raises Price Target to $296

Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has outperformed the market over the past 10 years by 1.99% on an annualized basis producing an average annual return of 11.56%. Currently, Oracle has a market capitalization of $364.61 billion. 
Buying $100 In ORCL: If an investor had bought $100 of ORCL stock 10 years ago, it would be worth $299.48 today based on a price of $130.02 for ORCL at the time of writing.
<h3>Oracle's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744901113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ORCL

Here's How Much $100 Invested In Oracle 10 Years Ago Would Be Worth Today

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17063712/Wuxi-XDC.png" alt="" class="wp-image-10875" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17063712/Wuxi-XDC.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17063712/Wuxi-XDC-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17063712/Wuxi-XDC-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Drugs services giant WuXi AppTec cashed in a stake in a sister firm to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another barrage
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>The sale of shares in WuXi XDC, a developer of antibody-drug conjugates, came a day before the U.S. president shocked markets with his tariff plan on April 2</li>
<li>The impact of any further punitive actions specifically targeting pharmaceutical products is hard to quantify at this point</li>
</ul>
Could tariff fever spread to the pharmaceutical sector? Medicines have been exempted for now from the import tax offensive launched this month by the United States, but drug producers are nervously scrutinizing their options and girding for battle.
A day before U.S. President Donald Trump delivered his "Liberation Day" tariff bombshell on April 2, one of China's top drug services companies sold off a block of shares in a sister firm specializing in bioconjugate research.
In doing so,&nbsp;WuXi AppTec&nbsp;(603259.SH; 2359.HK) was able to cash out its holdings at a favorable price, just before the unexpected scale of Trump's tariffs began sending financial markets into a tailspin.
Although the drugs industry was spared in that initial round of tariffs, President Trump has since vowed to bring in new levies on pharmaceutical products, spreading deep anxiety across the highly globalized sector.
In that light, the block sale of shares in&nbsp;WuXi XDC Cayman Inc.&nbsp;(2268.HK) appears to have been a preemptive move to hedge against tariff risks and a potential slide in market confidence.
After the market close on April 2, WuXi AppTec&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0402/2025040201523.pdf">announced</a>&nbsp;it had sold 50.8 million shares in its sibling company<a>&nbsp;</a>a day earlier for around HK$2.18 billion ($281 million). The sale was equivalent to around 4.23% of shares in WuXi XDC, a contract developer and producer of antibody-drug conjugates (ADCs) that was spun off as a separate entity within the WuXi biomedical group in 2023.
It was WuXi AppTec's third disposal of shares in the ADC services firm in the past half year, taking its cumulative proceeds to more than HK$4.6 billion.
The company said the money would be ploughed into boosting global production capability, cultivating its talent pool and strengthening its business model as an integrated provider of research, development and manufacturing services for the global pharmaceutical sector. The statement said the share sale produced an investment gain of around 1.85 billion yuan, representing more than 10% of its audited net profit attributable to parent company shareholders for the 2024 financial year.&nbsp;
In fact, WuXi AppTec is flush with cash to grow its business, with free cash flow reaching a record high of 7.98 billion yuan at the end of last year. Rather than build up its buffer, the company was likely looking to lock in profits and mitigate the potential damage from looming tariffs. As it happened, WuXi XDC's share price reached HK$49.5 per share on the day of the sale, the highest level since the company's IPO in November 2023.
That price peak was soon a distant memory, as the share dropped for four straight days on the general tariff shock. When the Hang Seng Index suffered a record one-day sell-off on April 7, WuXi XDC stock plunged 27.58% and is now trading around HK$30.
WuXi XDC's earnings had been looking good up to this point. In March the company reported annual revenues of 4.05 billion yuan for 2024, a year-on-year jump of nearly 91%. Net profit surged 277% to 1.07 billion yuan and net profit margin rose from 13.4% to 26.4%. Revenue from North America increased from 40% to 50% of the total, with China and Europe accounting for 26% and 16% respectively.
The stock encountered some turbulence last year in the months after its Hong Kong debut, but even this latest depleted level is 50% higher than the listing price of HK$20.6. A boom in demand for ADCs, a type of precision drug to fight cancer with fewer side effects than earlier treatments, is bolstering investor interest in the company.
The value of the global ADC market rose 24% to $13 billion in 2024, and six new ADC drugs together delivered sales exceeding $1 billion, fueling demand for research and development services. In its earnings report, WuXi XDC said it added 154 clients last year, bringing its total customer base to 499, including 13 of the top 20 pharma multinationals based on revenue.
<h4 class="wp-block-heading">How big is the tariff risk?</h4>
At this stage, the industry is struggling to quantify the scope and impact of the threatened pharmaceutical tariffs, given the sector's dispersed supply chains. A research note from China Securities said Chinese drugs contractors tend to export services to the United States in the late stage of research. When it comes to commercialization orders, Chinese companies may only carry out initial steps with the rest being fulfilled in European countries. If these activities are not covered by impending tariffs, the fallout for companies such as WuXi XDC could be limited.
That being said, raw materials and equipment costs could be inflated by tariffs, squeezing corporate profit margins. A senior executive at WuXi AppTec acknowledged the potential for damage, speaking on an April 10 earnings call. Vice Chairman and CIO Hu Zhengguo said the extent of the impact was unclear, but he vowed to work with customers to minimize the effects.
Like many Chinese companies, WuXi XDC has been offshoring production capacity to circumvent or blunt the effect of punitive U.S. actions. It has built a 22,000 square meter research and manufacturing site in a Singapore biomedical park that is due to go into operation at the end of this year, with production lines for ADCs and other formulations.
Meanwhile, drug multinationals served by the WuXi group have announced plans to boost U.S. production in moves that could affect the business of contract suppliers in the long term. For example, Novartis plans to invest at least $23 billion in U.S. infrastructure in the next five years to ensure key drugs destined for U.S. patients will be made locally. Meanwhile, Eli Lilly and Company will invest at least $27 billion to build four new U.S. production bases to meet growing demand for its best-selling diet and diabetes drugs.
WuXi XDC is trading at a price-to-earnings (P/E) ratio of 32 times, a significant premium over WuXi AppTec's 14 times. Investors need to keep a close eye on tariff developments, and general trade tensions, to gauge the implications for WuXi XDC's stock price. Whatever the company's growth potential, a market panic could take a heavy toll.

Asia

Health Care

Opinion

WuXi Group Wrestles With Uncertainty Over Pharma Tariffs

Evercore ISI Group analyst JESALYN Wong maintains Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Outperform and lowers the price target from $78 to $60.

Evercore ISI Group Maintains Outperform on Skechers USA, Lowers Price Target to $60

Evercore ISI Group analyst Jonathan Chappell maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Outperform and lowers the price target from $35 to $33.

Evercore ISI Group Maintains Outperform on CSX, Lowers Price Target to $33

Evercore ISI Group analyst Mark Lipacis maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and lowers the price target from $147 to $126.

Evercore ISI Group Maintains Outperform on Advanced Micro Devices, Lowers Price Target to $126

JMP Securities analyst Eric Ross maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Market Outperform and lowers the price target from $59 to $55.

JMP Securities Maintains Market Outperform on Red Rock Resorts, Lowers Price Target to $55

Evercore ISI Group analyst Michael Montani maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a In-Line and lowers the price target from $23 to $22.

Comments

Alibaba Gr Hldgs

Alibaba Gr Hldgs (BABAF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO